United States v. Glaxo Group Ltd.

From Food & Medicine Encyclopedia


United States v. Glaxo Group Ltd.[edit]

United States v. Glaxo Group Ltd. was a significant United States Supreme Court case decided in 1973. The case addressed issues related to patent law and antitrust law in the context of the pharmaceutical industry.

Background[edit]

The case arose from a dispute involving the Glaxo Group Ltd., a major pharmaceutical company, and the United States government. The government alleged that Glaxo had engaged in anticompetitive practices by using its patents to unlawfully extend its monopoly over certain pharmaceutical products.

Legal Issues[edit]

The primary legal issue in the case was whether Glaxo's use of its patents violated antitrust laws, specifically the Sherman Antitrust Act. The government argued that Glaxo's licensing agreements and patent practices restricted competition and maintained artificially high prices for its drugs.

Supreme Court Decision[edit]

The Supreme Court ruled in favor of the United States, holding that Glaxo's patent practices constituted an unlawful restraint of trade. The Court's decision emphasized the importance of balancing patent rights with the need to maintain competitive markets.

Impact[edit]

The decision in United States v. Glaxo Group Ltd. had a significant impact on the pharmaceutical industry and patent law. It reinforced the principle that patent rights cannot be used to justify anticompetitive behavior and highlighted the role of antitrust laws in regulating the use of patents.

Related pages[edit]

References[edit]

  • "United States v. Glaxo Group Ltd.," 410 U.S. 52 (1973).
  • "Antitrust and Patent Law: The Supreme Court's Decision in United States v. Glaxo Group Ltd.," Journal of Law and Economics.
Justice Byron White, who delivered the opinion of the Court in United States v. Glaxo Group Ltd.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:

Advertise on WikiMD

WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=United_States_v._Glaxo_Group_Ltd.&oldid=6303864"